Authors
CAPACITY-COVID Collaborative Consortium and LEOSS Study Group, M Linschoten, A Uijl, A Schut, CEM Jakob, LR Romão, RM Bell, E McFarlane, M Stecher, AGM Zondag, EPA van Iperen, W Hermans-van Ast, NC Lea, J Schaap, LS Jewbali, PC Smits, RS Patel, A Aujayeb, DP Ripley, M Saxena, C Spinner, GP McCann, AJ Moss, E Parker, S Borgmann, E Tessitore, S Rieg, MT Kearney, R Byrom-Goulthorp, M Hower, AK Al-Ali, AM Alshehri, AN Alnafie, M Alshahrani, YA Almubarak, FA Al-Muhanna, AM Al-Rubaish, F Hanses, AC Shore, C Ball, CM Anning, MM Rüthrich, PR Nierop, MJGT Vehreschild, SRB Heymans, MTHM Henkens, AG Raafs, ICC van der Horst, BCT Van Bussel, FJH Magdelijns, J Lanznaster, PY Kopylov, OV Blagova, K Wille, YM Pinto, JA Offerhaus, H Bleijendaal, C Piepel, JM ten Berg, WL Bor, M Maarse, C Römmele, RA Tio, NH Sturkenboom, L Tometten, CA den Uil, NTB Scholte, AL Groenendijk, S Dolff, LE Zijlstra, AD Hilt, M von Bergwelt-Baildon, BE Groenemeijer, U Merle, PM van der Zee, EA van Beek, K Rothfuss, FVY Tjong, ACJ van der Lingen, MZH Kolk, N Isberner, PS Monraats, M Magro, WRM Hermans, M Kochanek, G Captur, RJ Thomson, S Nadalin, GCM Linssen, T Veneman, R Zaal, C Degenhardt, FMAC Martens, EA Badings, R Strauss, AG Zaman, M Alkhalil, S Prasad, B Grüner, HE Haerkens-Arends, L Eberwein, P Dark, D Lomas, J vom Dahl, DO Verschure, K Hellwig, A Mosterd, D Rauschning, DJ van der Heijden, M Neufang, M van Hessen, C Raichle, L Montagna, SG Mazzilli, M Bianco, T Westhoff, A Shafiee, B Hedayat, E Saneei, H Porhosseini, B Jensen, L Gabriel, AG Er, BLJH Kietselaer, J Schubert, P Timmermans Jr, P Messiaen, A Friedrichs, FS van den Brink, P Woudstra, J Trauth, MIA Ribeiro, K de With, MMJM van der Linden, JT Kielstein, R Macías Ruiz, W Guggemos, E Hellou, P Markart, HAM van Kesteren, D Heigener, JK de Vries, S Stieglitz, JB Baltazar, I Voigt, DJ van de Watering, M Milovanovic, J Redón, MJ Forner, J Rüddel
Publication date
2021/3/12
Journal
MedRxiv
Pages
2021.03. 11.21253106
Publisher
Cold Spring Harbor Laboratory Press
Description
Aims
Patients with cardiac disease are considered high risk for poor outcomes following hospitalization with COVID-19. The primary aim of this study was to evaluate heterogeneity in associations between various heart disease subtypes and in-hospital mortality.
Method and results
We used data from the CAPACITY-COVID registry and LEOSS study. Multivariable Poisson regression models were fitted to assess the association between different types of pre-existent heart disease and in-hospital mortality. 16,511 patients with COVID-19 were included (21.1% aged 66 – 75 years; 40.2% female) and 31.5% had a history of heart disease. Patients with heart disease were older, predominantly male and often had other comorbid conditions when compared to those without. Mortality was higher in patients with cardiac disease (29.7%; n=1545 versus 15.9%; n=1797). However, following multivariable adjustment this difference was not significant (adjusted risk ratio (aRR) 1.08 [95% CI 1.02 – 1.15; p-value 0.12 (corrected for multiple testing)]). Associations with in-hospital mortality by heart disease subtypes differed considerably, with the strongest association for heart failure aRR (1.19 [1.10 – 1.30]; p-value <0.018) particularly for severe NYHA III/IV) heart failure (aRR 1.41 [95% CI 1.20 – 1.64; p-value <0.018]. None of the other heart disease subtypes, including ischemic heart disease, remained significant after multivariable adjustment. Serious cardiac complications were diagnosed in <1% of patients.
Conclusion
Considerable heterogeneity exists in the strength of association between heart disease subtypes and in-hospital mortality. Of all patients with …
Total citations
Scholar articles
… -COVID Collaborative Consortium and LEOSS Study … - MedRxiv, 2021